NWCI update Print E-mail
By M.E.Garza   
Tuesday, 06 April 2010 12:45

NewCardio, Inc. (NWCI.OB), the cardiac diagnostics company that we've been following for some time was up over 11% on "no news" this morning on very low volume. Sources tell us that good things are cooking behind the scenes.

First, the company may be close to announcing some positive revenue developments and second, we're assured that top management for both NewCardio and a "potential partner" company, which trades on a big exchange and plans to inject a substantial amount of money into the company, should be meeting in person this week.

Keep an eye on this stock. Many of our subscribers got in early and were able to double their money before it started to lose some momentum. It looks like the momentum may be coming back soon. This is a solid company with a very important technology that will no doubt spike up as some of these positive developments hit the news wires. The management team has a very clear vision of what they want to achieve and if they reach even 50% of their goals, this could be a $5 to $8 per share stock in twelve months.

Separately, first thing tomorrow morning, subscribers should be on the look-out for a cancer diagnostics company that will be featured as a trade alert. This big board company was trading at over five times the value of it's current stock price just a few months ago and now, after some restructuring and commercial sales distribution deals it looks like this stock is ready to move. That alert will be available to subscribers and it will be followed by a press release announcement regarding our special report and interview with the CEO of the company the following day.


Disclosure: Long NWCI




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter